Investigational drug · Phase 3
WS016
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hyperkalemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "WS016"
First trial start
2024
Dec 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "WS016", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hyperkalemia
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "WS016" as an intervention, largest first.
- A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of HyperkalemiaPivotal-lookingRecruiting
Waterstone Pharmaceutical (Wuhan) Co., LTD.Industry
NCT07251309 · 420 participants (planned) · Start Dec 23, 2024 · Primary completion Nov 2026
Drug: WS016; Placebo and 3 more · For: Hyperkalemia
Sites: Bengbu, China; Wuhu, China; Chongqing, China · 50 sites in all
- A Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of HyperkalemiaPivotal-lookingRecruiting
Waterstone Pharmaceutical (Wuhan) Co., LTD.Industry
NCT07881965 · 300 participants (planned) · Start Sep 25, 2026 · Primary completion Feb 20, 2029
Drug: WS016 · For: Hyperkalemia
Sites: Anqing, China; Hefei, China; Wuhu, China · 50 sites in all
- A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.Pivotal-lookingStatus unknown
Waterstone Pharmaceutical (Wuhan) Co., LTD.Industry
NCT06277128 · 140 participants (planned) · Start Sep 11, 2023 · Primary completion Apr 18, 2024
Drug: WS016 3g; WS016 6g and 2 more · For: Hyperkalemia
Sites: Beijing, China; Xiamen, China; Baoding, China · 26 sites in all
Waterstone Pharmaceutical (Wuhan) Co., LTD.Industry
NCT06281470 · 66 participants · Start Feb 13, 2023 · Primary completion Jun 15, 2023
Drug: WS016 Single Dose(6g); WS016 Single Dose(12g) and 8 more · For: Hyperkalemia
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Randomized Double-Blind Trial of WS016 in Chinese Patients With Hyperkalemia.
Sui Z, Zhao J, Ji ZH, et al. · Kidney Int Rep 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.